FDA approves first peanut allergy drug for kids

Gallery

MORE...

Sports

First Serve, AITA Partner to empower athletes through Wheelchair Tennis Championship

First Serve, an NGO founded by Reyaan Punj, recently organised the second edition of AITA

Bajrang Punia provisionally suspended by NADA, Paris berth at stake: Sources

Laureus Award 2024 : Novak Djokovic, Aitana Bonmati win top honours at Laureus Sports Awards

Asian Games medallist Jyothi Yarraji to train in Spain ahead of Paris Olympics

Lione Messi said Retirement not on my mind

Indian Wells: Alcaraz, Swiatek win titles

MORE...

FDA approves first peanut allergy drug for kids

Last Updated : 03 Feb 2020 04:48:30 PM IST

Peanut allergy

The US Food and Drug Administration (FDA) has approved the first drug to treat peanut allergies in children and teens.

Treatment with the drug, Palforzia, can be used for children between 4 and 17 years old with a confirmed diagnosis of peanut allergy, the FDA said in a statement.

The drug is designed to minimize the incidence and severity of a child's allergic reaction to peanuts, as even a small amount of exposure can be harmful to children with the allergy.

"When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.

Peanut allergy affects approximately one million children in the US and only one out of five of these children will outgrow their allergy.

Palforzia is a powder manufactured from peanuts and packaged in pull-apart capsules and a sachet, according to the FDA.

The powder is emptied from the capsules or sachet and mixed with a small amount of semisolid food -- such as applesauce, yogurt, or pudding.

The effectiveness of Palforzia is supported by a randomized, double-blind, placebo-controlled study conducted in the US, Canada and Europe in approximately 500 peanut-allergic individuals.